Quantum joins team to study PET tracer demyelination tracking
Quantum Biopharma is partnering with researchers at Massachusetts General Hospital in Boston on a clinical study to test a positron emission tomography (PET) tracer for monitoring changes in myelin content in people with multiple sclerosis (MS). The Phase 1 study (NCT04699747) is recruiting healthy adults and people…